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Abstract
Introduction: Hepatocellular adenoma (HA) is an uncommon benign hepatic tumour with the potential
for malignant change or spontaneous haemorrhage. Resection has been the recommended treatment,
but outcomes with other approaches are ill defined.
Methods: Demographic and outcomes data were retrospectively collected on patients diagnosed with
HA at a tertiary hepatobiliary centre from 1992–2011 whom underwent resection, bland embolization or
observation.
Results: In total, 52 patients with 100 adenomas were divided into single HA (n = 27), multiple HA
(n = 18), and adenomatosis (n = 7) groups. Eighty-seven per cent were female and 37% had a history of
hormone use. Median sizes of resected, embolized and observed adenomas were 3.6 cm, 2.6 cm and
1.2 cm, respectively. Forty-eight adenomas were resected as a result of suspicion of malignancy (39%) or
large size (39%); 61% of these were solitary. Thirty-seven were embolized for suspicion of malignancy
(56%) or hsemorrhage (20%); 92% of these were multifocal. Two out of three resected adenomas with
malignancy were 10 cm and recurred locally [4%, confidence interval (CI) 1–14%]. Ninety-two per cent
of the embolized adenomas were effectively treated; three persisted (8.1%, CI 2–22%). Most observed
lesions did not change over time.
Conclusions: While solitary adenomas are often resected, multifocal HAs are frequently embolized.
Small adenomas can safely be observed. Given low recurrence rates, select HAs can be considered for
embolization.
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Introduction
Hepatocellular adenoma (HA) is a rare benign hepatic tumour.
Patients diagnosed with HA are usually female of reproductive age
with a history of oral contraceptive (OCP) use.1 They are also
found in men taking anabolic steroids or those with glycogen-
storage or iron-overload disorders.2 The incidence of HA has
increased from 5 patients per million in 19643 to 4 patients per
100 000 currently,4 for reasons that are unclear. In parallel, there
are increased reports of disease complications such as spontane-
ous haemorrhage.5 In the United States, a multicentre analysis of
124 patients showed that HA rupture is associated with recent
hormonal use and increasing tumour size.5 There is no consensus
on whether patients with a solitary HA have different risks
and complications than those with hepatic adenomatosis.
Adenomatosis, defined as at least 10 lesions, has been reported in
small studies to be more common in men and is historically
associated with an increased risk of malignant transformation and
haemorrhage.6
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Histologically, hepatic adenomas are composed of normal
hepatocytes, lacking biliary elements, surrounded by a stromal
capsule, with decreased mitotic elements.5 The understanding of
HA is evolving with subtype classifications of adenoma character-
istics that may be implicated in the progression to hepatocellular
carcinoma (HCC) or haemorrhage. Recently, the molecular
mechanism has been further defined with b-catenin mutations
associated with HA at risk for HCC and hepatocyte nuclear factor
1a (HNF1a) mutations associated with steatotic lesions.7 A
single-centre study of 122 patients in France showed that patients
with adenomas greater than 5 cm, telangiectatic or unclassified
subtypes, or male gender were more likely to have HCC and/or
haemorrhage and thus should undergo resection.
Traditionally, resection has been recommended to prevent
or treat malignant transformation or haemorrhage. In the last
decade, less invasive alternatives to surgery have been imple-
mented, such as radiofrequency ablation8 and transcatheter-
arterial embolization.4,9 Currently, there is no agreement on the
efficacy of less invasive or observational approaches to treat
adenomas. This study reviews factors associated with malignant
transformation and haemorrhage as well as efficacy and prognosis
of different treatment modalities for patients with HA.
Methods
Permission was obtained from the Institutional Review Board
for this retrospective review of 52 patients diagnosed with HA
from 1992 to 2011. Demographic and outcome data were retro-
spectively reviewed from electronic medical records, including
clinical, intra-operative and pathological data. Diagnosis was
based on radiographical appearance or histology. A subset of
patients in this study were discussed in a prior publication from
our institution.4
Patient demographics
Patients were divided into three groups: solitary HAs, multiple
HAs (2–9 lesions) and adenomatosis ( 10 lesions). The param-
eters analysed were age, gender, body mass index (BMI), current
or past history of a cancer and any hormone use. Recent hormone
use was defined as within 6 months of initial presentation. The
comorbidities analysed were diabetes mellitus (DM), hypercho-
lesterolaemia, Turner’s syndrome, liver disease, intellectual dis-
ability and fertility disorders requiring hormone replacement
therapy (HRT). Pre-operative symptoms, liver function tests
(LFTs) and pre-operative biopsies were also noted.
Tumour factors
In patients treated non-operatively, a diagnosis of HA was made
on imaging. Of the 36 patients with resections, 28 had slides
available for retrospective histological re-review. Adenomas with
questionable HCC components remained in the data analysis.
One patient who was clinically reported to have an adenoma was
found to have characteristics of focal nodular hyperplasia (FNH)
on pathological review and was excluded. For adenoma subtype
classification, a specialized pathologist at MSKCC classified the
available tissues using the four-type Zucman–Rossi classifica-
tion.7,10 Type I is steatotic which often has an HNF1a mutation
(Fig. 1). Type II often has a b-catenin mutation, shows acinar
structures with cytological atypia and is often confused with well-
differentiated HCC. Type III is the inflammatory type with IL-6
pathway activation, sinusoidal dilatation and congestion, and
thick-walled arteries. Type IV is unclassified because it has no
mutations or signs of inflammation. Five slides were selected for
b-catenin immunohistochemical staining to help differentiate
between Type II and Type IV.
Tumour size was recorded as the two largest dimensions in
centimetres by pathological evaluation for those resected and by
Figure 1 Representative micrographs of subtypes of hepatocellular adenoma (HA). (a) Type I with a prominent fatty change; (b) Type II with
noticeable hepatocellular nuclear atypia; and (c) Type III with telangiectatic sinusoid dilatation and scattered inflammatory cell infiltration
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imaging for those embolized or observed. Multiple adenomas
treated by serial embolization or multiple resections were coded as
separate treatments. Patients were placed in multiple treatment
groups if more than one treatment modality was employed.
Outcomes analysis
Outcome data included total LOS related to treatments, treatment
efficacy and follow-up time. Disease status was reported as alive
with disease (AWD) or no recurrence. For the small subset of
patients with HCC associated with adenomas, status was indicated
as AWD and no evidence of disease (NED).Death was indicated as
dead of other cause (DOO), dead of unknown cause (DOU) or
dead of complications (DOC). Local recurrence was defined as a
new lesion at the same site of a treated lesion. Persistent lesions
were also reported.
Statistical analysis
Categorical variables were presented using frequencies and
percentages and compared using the chi-square test. Continuous
variables were summarized using median (range) and com-
pared using rank-based methods (Wilcoxon’s test for two groups
and the Kruskal–Wallis test for three groups). The failure
rates were reported as percentages with confidence intervals.
All statistical analyses were conducted using STATA v 8.0 (Stata
Corp., College Station, TX, USA) and R v2.14 (http://www.
r-project.org).
Results
Patient demographics
Between 1992 and 2011, 52 patients were identified with HA. Of
these, 45 (86.5%) were female and 19 (36.5%) had a history of
recent hormone use. Twenty-four patients (46%) had symptoms
such as abdominal pain and 8 patients (15.4%) had elevated liver
function tests. Themedian age of all patients was 39 years (34–49).
Twenty-nine (55.8%) of the patients hadmore than one adenoma.
There were a total of 100 lesions. The median follow-up for these
patients was 1.8 years (1 day–18 years).
The median age of the three groups did not vary significantly
[39 (33–50); 38 (31–43) and 44 (37–49), respectively, P = 0.35]
(Table 1). The median body mass indexes (BMIs) were 23.9 kg/m2
(17.9–44.1) for single HA patients, 26.4 kg/m2 (18.3–42.7) for
multiple HA patients and 27.8 kg/m2 (21.4–41.8) for the adeno-
matosis patients (P < 0.001). A history of some form of cancer
existed in up to 20 out of 52 patients (38%) in the three study
populations with no clinically significant differences (P = 0.63).
Rates of recent hormone use were not different between the three
groups (P = 0.92). Of the six comorbidities studied, there was
no significant difference in prevalence between the three groups
(P = 0.09–1). There was no difference in pre-operative symptoms
between the groups (P = 0.86), or in elevated liver function tests
(0 = 0.75). More patients with adenomatosis (6 out of 7 patients)
had pre-operative biopsies than patients with multiple HAs (8 out
of 18 patients) and single HAs (6 out of 27 patients) with signifi-
cant differences between the solitary and adenomatosis groups
(P = 0.01) only. The median follow-up for those resected, embol-
ized and observed were 1.8, 4.7 and 1.6 years, respectively
(Table 2). Embolized follow-up time was significantly different
(P = 0.001) from resected and observed follow-up times, which
were similar (P = 0.59).
Adenoma demographics
Of the 100 adenomas, there were 70 adenomas (70%) less than
5 cm in size, 22 adenomas (22%) that were 5 to 9.9 cm and 8
adenomas (8%) greater than 10 cm. The lesions were evenly dis-
tributed amongst each hepatic sector with 22 lesions in the right
anterior, 33 in the right posterior, 19 in the left medial and 26 in
the left lateral sectors. Forty-eight adenomas with a median size
of 3.6 cm (0.7–23) were resected in 36 operations (Table 2).
Thirty-seven adenomas with a median size of 2.6 cm (0.5–9.9)
were treated by 25 embolizations. Fifteen adenomas with a
median size of 1.2 cm (0.6–6.3) were observed. The median
sizes between each treatment group were significantly different
(P < 0.01).
Intervention
Treatment categories included either resection or bland emboli-
zation. There were a total of 43 operations including 20 wedges/
segmentectomies, 15 enucleations, 7 lobectomies and one
trisegmentectomy. The median estimated blood loss was 200 ml
(0–10 l). The most common indications for resection were a sus-
picion of malignancy (14 of 36 resections) and large size (14 of 36
resections) (Table 3a). The most common indication for emboli-
zation was also suspicion of malignancy (14 of 25 embolizations)
(Table 3b). A clinical haemorrhage or risk of a haemorrhage was
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Figure 2 The size of the adenoma was traced over time after
embolization
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the second most common indication (5 of 25 embolizations) for
embolization. Other reported indications for intervention were
rapid growth with 0.5 cm/month and 1.0 cm/month increase in
size for two adenomas, positron emission tomography (PET) avid
lesions and an inability to discontinue hormone therapy needed
for fertility or growth treatment. The majority of resections (22 of
26 resections) were of solitary lesions. The majority of emboliza-
tions (23 of 25 embolizations) were of multifocal lesions. There
were three patients who had pre-operative embolizations and one
who had an embolization post-resection for a local recurrence; all
were placed in the resection treatment group. One patient had an
embolized adenoma that disappeared but later underwent resec-
tion for recurrence and was analysed in the embolization treat-
ment group. The most common indication for observation was a
small lesion that remained stable on imaging (Table 3c).
Overall, there were 20 out of 52 patients (39%) with HA who
underwent a biopsy. Of the 36 resected patients, 10 (28%) had
pre-operative biopsies that showed benign adenoma. Final patho-
logical evaluation confirmed these findings in nine specimens,
whereas one of these ten patients (10%) who had biopsy-proven
adenoma had a final pathology showing malignant transfor-
mation. Two of these ten patients (20%) with biopsy-proven
adenoma also had a haemorrhage indicated on imaging: one was
related to the biopsy procedure and one was as a result of persist-
ent bleeding after embolization. Of the 26 resected patients
without a pre-operative biopsy, there were two patients (7.7%)
with HCC: one with an initial HCC that recurred and one
that recurred as an HCC from an adenoma. Of these 26 resected
patients without pre-operative biopsies, one (3.8%) had a resec-
tion for clinical haemorrhage indicated on imaging and two
patients (7.7%) were resected for rapid growth and large size, but
found to have microscopic haemorrhage on final pathology. Of
the 25 embolized patients, 7 patients underwent biopsies that
showed benign pathology in addition to one patient who was also
included in the resection group. None of these eight patients had
malignant transformation or haemorrhage. Of the nine observed
patients, three had biopsies showing benign adenoma in addition
to two other patients with multiple adenomas who were included
in the resection group. None of these five patients or the four
without pre-operative biopsies went on to develop either malig-
nant transformation or a haemorrhage. Liver pathology in addi-
tion to hepatic adenomas existed in many patients. Twenty of the
30 patients with reviewable pathology slides had steatosis and one
patient had cirrhosis.
Table 1 Patient demographic data were divided into three clinical groups
Single HA Multiple HAs (2–9) Adenomatosis (10) P-value All adenomas
N = 27 patients
(51.9%)
N = 18 patients
(34.6%)
N = 7 patients
(13.5%)
Between the
three groups
N = 52 patients
(100%)
Age median (IQR) (years) 39 (33–50) 38 (31–43) 44 (37–49) 0.35 39 (34–49)
Female 24 15 6 0.86 45 (86.5%)
Male 3 3 1 0.93 7 (13.5%)
BMI (median) 24 (17.9–44.1) 26 (18.3–42.7) 28 (21.4–41.8) <0.001 25.1 (17.9–44.1)
Any hormone use 13 8 4 0.93 25 (48.1%)
Recent (within 6 months)
hormone use
10 6 3 0.92 19 (36.5%)
Comorbidities
DM 3 4 1 0.66 8 (13.4%)
Hypercholesterolemia 3 1 1 0.68 4 (7.7%)
Turner's syndrome 3 2 1 1.0 4 (7.7%)
Liver disease 2 3 1 0.49 6 (11.5%)
Intellectual disability 0 3 1 0.09 4 (7.7%)
Fertility treatment 0 3 0 0.08 3 (5.8%)
Pre-operative biopsy 6 8 6 0.01 20 (38.5%)
HA, hepatocellular adenoma; IQR, interquartile range; DM, diabetes mellitus.
Table 2 Adenomas were divided into three treatment groups with follow-up time and size recorded. Median sizes between each resection
group were significantly different (P < 0.01)
Intervention No. of patients Median follow-up time No. of adenomas Median size (cm)
Resection 35 1.8 years (22 days–18 years) 48 3.6 (0.7–23)
Embolization 13 4.7 years (5.1 months–13.8 years) 37 2.6 (0.5–9.9)
Observation 9 1.6 years (1 day–7.8 years) 15 1.2 (0.6–6.3)
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Outcomes
In the total cohort, 5 out of 52 patients (9.2%) had local
recurrence or persistent disease requiring a second inter-
vention (Table 4). Of the 48 adenomas resected, 2 single HAs
that were both greater than or equal to 10 cm in size recurred
locally (recurrence rate 4.2%, CI 1–14%). One patient had
a local recurrence detected on magnetic resonance imaging
4 months after an initial lobectomy and underwent a second
resection 10 months later. The other patient had an emboliza-
tion 5.5 years after an initial enucleation. There were 2 other
resected patients of 36 who developed solitary lesions in new
locations in the liver 17.5 years later. The total length of stay
(LOS) in the hospital for a resection was a median of 7 days
(2–33).
Of thirty-seven adenomas embolized, three persistent lesions
(8.1%, CI 2–22%) required second interventions. All other lesions
disappeared (5 adenomas), decreased in size (22 adenomas) or
remained stable (7 adenomas) after one embolization (Fig. 2).
Table 3 (a) Indications for each resection were reported for the three clinical groups. Outcomes by resected adenomas were indicated. (b)
Indications for each embolization were reported for the three clinical groups. Outcomes by embolized adenomas were indicated. (c)
Indications for each observation were reported for the three clinical groups. *Patients in these three groups overlapped in all three groups
making the sum larger than 52 patients
Table 3a Resection indications and outcomes
Solitary (61.1%) Multifocal (38.9%) Overall
Single HA Multiple HAs (2–9) Adenomatosis (10)
Resections 22 12 2 36
Indication for intervention
Suspicion of malignancy 8 4 2 14
Large size 9 5 0 14
Clinical haemorrhage 3 0 0 3
Growth 1 2 0 3
PET + 1 0 0 1
Continuous HRT 0 1 0 1
Adenomas resected 22 19 7 48
Local recurrence 2 0 0 2 (4.2%, CI [1–14%])
Patients* 22 11 2 35
HA, hepatocellular adenoma; PET; positron emission tomography.
Table 3b Embolization indications and outcomes
Solitary (8%) Multifocal (92%) Overall
Single HA Multiple HAs (2–9) Adenomatosis (10)
Embolizations 2 16 7 25
Indication for Intervention
Suspicion of malignancy 1 10 3 14
Large size 0 1 0 1
Haemorrhage 5
Risk of haemorrhage 0 3 1
Clinical haemorrhage 0 1 0
PET + 1 0 2 3
Continuous HRT 0 1 1 2
Adenomas embolized 2 24 11 37
Persistent disease 1 2 0 3 (8.1%, CI 2–22%)
Disappeared 1 2 2 5
Decreased in size 0 14 8 22
Stable size 1 5 0 7
Patients* 2 6 5 13
HA, hepatocellular adenoma; PET, positron emission tomography; CI, confidence interval.
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The failure rate was not significantly different from that of a
resection (P = 0.65). Two persistent lesions in the multiple HA
group underwent second embolizations 3.7 months and 4.5
months after the initial treatment, respectively. One lesion disap-
peared and one decreased in size from 4.7 to 2.6 cm in 9 months.
The third persistent lesion was in the single HA group and under-
went a resection. The total LOS in the hospital for embolization
was a median of 4 days (3–6).
Of the 15 lesions observed, 1 lesion disappeared, 3 lesions
decreased in size and 11 lesions remained stable. None of
these lesions progressed. The majority of lesions were less
than 2 cm in diameter and the only lesion greater than 5 cm
was observed while the patient underwent gastric bypass
for morbid obesity. Seven out of nine of these patients were
asymptomatic.
Adenoma pathology
Of the 36 patients who underwent a resection (35 from the resec-
tion group and one who was embolized and then resected), 28 had
material available for classification into the four types (Table 5).
The five lesions immuno-stained for b-catenin to help differenti-
ate type II from IV were negative so these adenomas were placed
in the unclassified group. Steatosis was identified in varying
degrees in each of the subtypes (Table 5). Table 6 demonstrates
the demographics of the patients who had malignant transforma-
tion. Three adenomas (3% of all 100 adenomas, 5.8% of 52
patients) had evidence of malignancy on final pathology (6.3% of
48 resected adenomas) (Fig. 3). All three were males (3 of 7 male
patients). The three patients with HCC had 1–2 lesions and did
not have any history of hormone use. None of the lesions were
thought to be cancer at the time of pre-operative evaluation.
Table 3c Observation indications and outcomes
Solitary (30%) Multifocal (70%)
Single HA Multiple HAs (2–9) Adenomatosis (10) Overall
Observations 3 4 3 10
Indication for observation
Stable disease 2 3 3 8
Pregnant 0 1 0 1
Withheld OCP 1 0 0 1
Adenomas observed 3 7 5 15
Disappeared 0 1 0 1
Decreased in size 2 0 1 3
Stable size 1 6 4 11
Patients* 3 4 2 9
HA, hepatocellular adenoma; OCP, oral contraceptive.
Table 4 The treatment and time interval between treatments for each of five treatment failures
Group Size of initial
lesion (cm)
1st treatment Type of recurrence 2nd treatment Time interval between
procedures (months)
Status
Multiple 3.2 Embolization Persistent disease Embolization 3.7 AWD
Multiple 5.5 Embolization Persistent disease Embolization 4.5 AWD
Single 4.2 Embolization Persistent disease Resection 4.4 No recurrence
Single 11.5 Resection Local recurrence Embolization 66 AWD
Single 10 Resection Local recurrence Resection 10 No recurrence
AWD, alive with disease.
Table 5 Adenoma pathologic subtypes
Type 1 Type 2 Type 3 Type 4
Steatotic Telangiectatic Unclassified
Patients (n) 12 2 8 6
Molecular mutation HNF 1 alpha B-catenin IL-6 pathway activation No mutation
Steatosis 12 1 4 4
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Malignant transformation in the single, multiple and adenoma-
tosis groups occurred in 2 out of 27, 1 out of 18 and none out of
7 patients, respectively (P = 0.76). Two of the patients with HCC
had a local recurrence after a resection of large lesions >10 cm in
size. Of the three patients with malignancy, the one patient with
reviewable pathology had Type IV pathology. The third patient
had multiple lesions with a pre-operative biopsy indicating a
benign lesion that was HCC on final pathology. This patient died
8 years later of metastatic mucinous adenocarcinoma of the
peritoneum. No patients died of HCC.
A clinical haemorrhage was suspected in four patients treated
with a resection. Two of these patients had haematomas noted on
gross pathology. Two patients who underwent a resection for
growth and large size showed evidence of a microscopic haemor-
rhage. In total, there were four confirmed haemorrhages (4% of
100 all adenomas, 8.3% of 48 resected adenomas), consisting of
two clinical and two microscopic hemorrhages. A haemorrhage
occurred in 3 out of the 27 single HA patients, 1 out of 18 multiple
HA patients and none of the 7 adenomatosis patients (P = 0.57).
The median size of these HA was 5.9 cm (3–8.2).
Discussion
Determining treatment options for hepatic adenomas is impor-
tant because of the increase in incidence of these liver tumours.
Multiple studies have developed criteria revolving around tumour
size, tumour number, hormone use, gender and more recently
tumour pathology to help determine which patients require
treatment.2,5,11 Historically, resection was the primary mode of
treatment to prevent disease complications such as malignant
transformation and haemorrhage. However, a resection is often
not feasible in patients with adenomatosis. This obstacle led to
expansion of the treatment algorithm to include liver transplan-
tation.12 However, Dokmak et al. 2 concluded that the risk of com-
plications does not increase with the number of adenomas and
therefore liver transplantation is not necessary. Given the utiliza-
tion of hepatic arterial embolization for HCC, it is also an option
for the treatment of HA. The role of embolization and observa-
tion is, however, unclear.
Our first objective was to examine the demographics of the
patients who have HA. The overall impression from the entire
patient cohort is that most patients with HA are middle-aged
females frequently with a history of hormone use and steatosis.
However, given this is a heterogenous group, we sought to deter-
mine whether any differences existed between the three clinical
groups: single HA, multiple HAs and adenomatosis.We found no
differences in age, gender or recent hormone use between the
three groups. In addition, we found the malignancy rate in the
single, multiple and adenomatosis groups were similar. In 1985,
Flejou et al. reported a higher complication rate and higher OCP
use in those with adenomatosis,6 but more recent reports
have disputed this.2 A higher BMI, however, correlated with the
population with more adenomatous lesions as reported byTa
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Bunchorntavakul et al.13 There were higher rates of intellectual
disability in the multiple HA and adenomatosis groups compared
with the solitary HA group in our study. This represents patients
with Turner’s syndrome. Turner’s syndrome is caused by mono-
somy X and is characterized by phenotypic features such as short
stature, low set ears, webbed neck, intellectual disability, gonadal
dysfunction and sterility. These patients have an increased risk of
cancers, but it is unclear if this risk includes HCC.14
Malignant transformation was present in 5.8% of our popu-
lation of 52 patients, which is similar to previously published
rates.11,15,16 HCC was found in 3 (8.3%) of all 36 patients who
were selected for resection.17 The risk of malignancy from
biopsy-proven adenoma (10%) is similar to the risk without
biopsy (7.7%). In our patient population, three (42.9%) of all
seven males developed HCC. This high rate of malignancy is
consistent with other previous reports.2 Size has also been asso-
ciated with the risk of malignancy. We found that the two
patients with a single adenomas and HCC were both adenomas
greater than 10 cm. The third patient with HCC in our cohort
was a patient with multiple hepatic adenomas who had HCC in
one of the adenomas that was resected. Deneve et al. described a
4% risk of malignancy in resected hepatic adenomas, all in
adenomas greater than 8 cm in size. It is likely that gender is a
risk factor for malignancy in patients with both single and mul-
tiple adenomas, but it is unclear if size is a risk factor only for
patients with single adenomas. A pathological review was not
possible for all three patients with HCC, so the malignancy risks
of different pathologic subtypes cannot be addressed in this
study.
Spontaneous haemorrhage has been described as the most
common complication of HA. We found a haemorrhage was
present in 7.7% in our population. A biopsy was performed in
patients (20%) with highly suspicious but vascularized adenomas
and caused a haemorrhage in one. A smaller percentage (3.5%)
underwent a resection instead of a biopsy first for a haemorrhage
indicated on imaging, whereas a similar percentage (7.7%) under-
went a resection and was found to have an occult haemorrhage.
The rates of histologically proven haemorrhage in the single,
multiple and adenomatosis groups were similar. Dokmak et al.
reported that haemorrhage (as identified on imaging) was present
in 21% of patients with HA.2 Pre-operative embolization may be
useful to stabilize a patient with a spontaneous haemorrhage.18 In
addition, embolization can be used to decrease vascularity prior to
resection in adenomas that are thought to be hypervascular on
pre-operative imaging. Pre-operative embolization was utilized in
three of our patients.
It is difficult to make a direct comparison between resection,
embolization and observation in this patient cohort. Most resec-
tions were performed for single adenomas, whereas most emboli-
zations were performed for multifocal adenomas. The local failure
rate (local recurrence or persistent disease) was, however, similar
between resection (4.2%) and embolization (8.1%). There are
multiple management options described for asymptomatic HAs
smaller than 5 cm.2,5,9 These include observation while withhold-
ing hormones, resection, transplantation for multifocal disease,
radiofrequency ablation and embolization.8,19,20 Most adenomas
do not, however, regress with cessation of hormone use.4 Radiof-
requency ablation is also not an optimal treatment owing to the
size of many adenomas.21 In search of less invasive approaches
than a resection, embolization has been utilized at this centre. A
retrospective review over 24 months by Deodhar et al. examined
the outcome of 8 patients treated with bland embolization.
Figure 3 A representative lesion of hepatocellular adenoma (HA) with transformation to hepatocellular carcinoma (HCC). (a) A nodular
hepatocellular neoplasm with a rim of HA and transformed HCC. (b) HCC reveals increased cytological atypia, high nuclear to cytoplasmic
(N/C) ratio and pseudoglandular formation. Adjacent HA comprises bland appearing hepatocytes with a low N/C ratio. (c) Well-differentiated
HCC transformed from the HA
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Regression was observed in 81% of the 16 lesions.4 Post-
embolization, both Deodhar et al. and Stoot et al. found that
adenoma tissue regressed and in some patients was not detectable
on follow-up imaging.4,18 Our data, which includes patients from
the Deodhar et al. study, demonstrates in a larger cohort that
embolization is durable. We found that large adenomas that were
embolized regressed on follow-up imaging.
Results of observing patients with adenomas were limited by
the small number of patients in this group and the relatively short
follow-up time for what is often a slow-growing benign tumour.
In this study, 14 out of 15 lesions observed were less than 3 cm.
The outcomes of observation revealed that all lesions in the nine
patients disappeared, decreased in size or remained stable. The
one patient with an adenoma that regressed was a 22-year-old
male with a 0.9-cm size adenoma that regressed over 2.7 years
along with three other lesions that were embolized. None of the
observed patients developed complications. Of the 15 lesions that
were observed, 6 were in patients who were never exposed to HRT
and 1 lesion remained stable when HRT was withheld. Deneve
et al. reported observing patients with similar characteristics
(observation for lesions <3 cm, asymptomatic, not growing).5
Although follow-up is relatively short for these slow-growing
tumors, it is reasonable to consider observation in patients with
small, asymptomatic tumors that appear consistent with adeno-
mas on imaging studies.
The data from this tertiary referral centre with a concentrated
proportion of patients harbouring single and multifocal adeno-
mas shows that embolization and observation are reasonable
treatment options in select patients. With increased OCP use,
females with solitary lesions that are suspicious for malignancy
and large size should undergo resection as should males given the
high risk of malignancy associated with male gender. Vigilance in
staining and subtyping resected lesions would help future risk
stratification for developing HCC. Females withmultifocal disease
who have lesions suspicious of malignancy or concerning for
haemorrhage owing to hypervascularity should be considered for
embolization. Smaller lesions may be observed safely. With low
local recurrence and adenoma persistence, gender, radiological
appearance, vascularity and size can be used to indicate appro-
priate treatments to prevent malignant transformation and
haemorrhage. Given the success of embolization in patients with
multifocal disease, it is reasonable to consider expanding the
indications for embolization in select patients.
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